1.
BMC Nephrol
; 25(1): 216, 2024 Jul 06.
Article
in English
| MEDLINE
| ID: mdl-38971750
ABSTRACT
The contribution of chronic kidney disease (CKD) towards the risk of developing cardiovascular disease (CVD) is magnified with co-existing type 1 or type 2 diabetes. Lipids are a modifiable risk factor and good lipid management offers improved outcomes for people with diabetic kidney disease (DKD).The primary purpose of this guideline, written by the Association of British Clinical Diabetologists (ABCD) and UK Kidney Association (UKKA) working group, is to provide practical recommendations on lipid management for members of the multidisciplinary team involved in the care of adults with DKD.
Subject(s)
Diabetic Nephropathies , Humans , Diabetic Nephropathies/therapy , Adult , United Kingdom/epidemiology , Cardiovascular Diseases/therapy , Lipids/blood , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/therapy , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
2.
Diabet Med
; 41(8): e15383, 2024 Aug.
Article
in English
| MEDLINE
| ID: mdl-38859632
Subject(s)
Diabetes Mellitus, Type 2 , Kidney Transplantation , Sodium-Glucose Transporter 2 Inhibitors , Humans , Sodium-Glucose Transporter 2 Inhibitors/therapeutic use , Diabetes Mellitus, Type 2/drug therapy , Female , Male , Middle Aged , Diabetic Nephropathies , Hypoglycemic Agents/therapeutic use , Hypoglycemic Agents/adverse effects , Treatment Outcome , Aged , Transplant Recipients , Benzhydryl Compounds/therapeutic use , Benzhydryl Compounds/adverse effects , Adult
3.
J Assoc Physicians India
; 72(6): 11-13, 2024 Jun.
Article
in English
| MEDLINE
| ID: mdl-38881127